

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/822,053
Filing Date	April 8, 2004
First Named Inventor	Robert Graham Feldman
Art Unit	1645
Examiner Name	NAVARO
Attorney Docket Number	GJE-44D1

Sheet

1

of

3

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
~	U1	US-5,876,931	03-02-1999	Holden	All
~	U2	US-5,643,579	07-01-1997	Hung et al.	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T* <sup>6</sup>
~	F1	EPO 0889120 B1	01-07-1999	Microscience Limited	All	
~	F2	WO 00/14240	03-16-2000	CREATOGEN BIOSCIENCES GMBH	All	
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner  
Signature

MARK NAVARO

Date

Considered

11/29/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/822,053	
			Filing Date	April 8, 2004	
			First Named Inventor	Robert Graham Feldman	
			Group Art Unit	1645	
Examiner Name	NAVARRO				
Sheet	2	of	3	Attorney Docket Number	GJE-44D1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
~	R1	MEDINA, E. <i>et al.</i> "Pathogenicity Island 2 Mutants of <i>Salmonella typhimurium</i> Are Efficient Carriers for Heterologous Antigens and Enable Modulation of Immune Responses", <i>Infection and Immunity</i> , 1999, pp. 1093-1099, Vol. 67, No. 3.	
~	R2	VALENTINE, P.J. <i>et al.</i> "Identification of Three Highly Attenuated <i>Salmonella typhimurium</i> Mutants That Are More Immunogenic and Protective in Mice than a Prototypical <i>aroA</i> Mutant", <i>Infection and Immunity</i> , 1998, pp. 3378-3383, Vol. 66, No. 7.	
~	R3	HENSEL, M. <i>et al.</i> "Genes Encoding Putative Effector Proteins of the Type III Secretion System of <i>Salmonella</i> Pathogenicity Island 2 are Required for Bacterial Virulence and Proliferation in Macrophages", <i>Molecular Microbiology</i> , 1998, pp. 163-174, Vol. 30, No. 1.	
~	R4	HENSEL, M. <i>et al.</i> "Analysis of the Boundaries of <i>Salmonella</i> Pathogenicity Island 2 and the Corresponding Chromosomal Region of <i>Escherichia coli</i> K-12", <i>Journal of Bacteriology</i> , 1997, pp. 1105-1111, Vol. 179, No. 4.	
~	R5	HENSEL, M. <i>et al.</i> "Functional Analysis of <i>ssaJ</i> and <i>ssaK/U</i> Operon, 13 Genes Encoding Components of the Type III Secretion Apparatus of <i>Salmonella</i> Pathogenicity Island 2", <i>Molecular Microbiology</i> , 1997, pp. 155-167, Vol. 24, No. 1.	
~	R6	SHEA, J.E. <i>et al.</i> "Influence of the <i>Salmonella typhimurium</i> Pathogenicity Island 2 Type III Secretion System on Bacterial Growth in the Mouse", <i>Infection and Immunity</i> , 1999, pp. 213-219, Vol. 67, No. 1.	
~	R7	SHEA, J.E. <i>et al.</i> "Identification of a Virulence Locus Encoding a Second Type III Secretion System in <i>Salmonella typhimurium</i> ", <i>Proc. Natl. Acad. Sci. USA</i> , 1996, pp. 2593-2597, Vol. 93.	
~	R8	CHATFIELD, S. N. <i>et al.</i> "Construction of a Genetically Defined <i>Salmonella typhi</i> Ty2 <i>aroA</i> , <i>aroC</i> Mutant for the Engineering of a Candidate Oral Typhoid-Tetanus Vaccine", <i>Vaccine</i> , 1992, pp. 53-60, Vol. 10, No. 1.	
~	R9	LEVINE, M.M. <i>et al.</i> "Attenuated <i>Salmonella</i> as Live Oral Vaccines Against Typhoid Fever and as Live Vectors", <i>Journal of Biotechnology</i> , 1996, pp. 193-196, Vol. 44, No. 1-3.	
~	R10	DOUGAN, G. <i>et al.</i> "Live Bacterial Vaccines and Their Application as Carriers for Foreign Antigens", <i>Advances in Veterinary Science and Comparative Medicine</i> , 1989, pp. 277-300, Vol. 33.	
~	R11	HOHMANN, E.L. <i>et al.</i> "Evaluation of a <i>phoP</i> <i>phoQ</i> -deleted, <i>aroA</i> -deleted Live Oral <i>Salmonella typhi</i> Vaccine Strain in Human Volunteers", <i>Vaccine</i> , 1996, pp. 19-24, Vol. 14, No. 1.	
~	R12	LOWE, D.C. <i>et al.</i> "Characterization of Candidate Live Oral <i>Salmonella typhi</i> Vaccine Strains Harboring Defined Mutations in <i>aroA</i> , <i>aroC</i> , and <i>htrA</i> ", <i>Infection and Immunity</i> , 1999, pp. 700-707, Vol. 67, No. 2.	
~	R13	SCHODEL, F. <i>et al.</i> "Hepatitis B Virus Nucleocapsid/pre-S2 Fusion Proteins Expressed in Attenuated <i>Salmonella</i> for Oral Vaccination", <i>Journal of Immunology</i> , 1990, pp. 4317-4321, Vol. 145, No. 12.	

Examiner Signature	MARK NAVARRO	Date Considered	11/29/05
--------------------	--------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete If Known</b>		
			Application Number	10/822,053	
			Filing Date	April 8, 2004	
			First Named Inventor	Robert Graham Feldman	
			Group Art Unit	1645	
			Examiner Name	NAVARRO	
Sheet	3	of	3	Attorney Docket Number	GJE-44D1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
~	R14	PLOTKIN, S. A. <u>Vaccines</u> , 1988, p. 571, W.B Saunders Co., Philadelphia.	
	R15		
	R16		
	R17		
	R18		
	R19		
	R20		
	R21		
	R22		
	R23		
	R24		
	R25		
	R26		

Examiner Signature	MARK NAVARRO	Date Considered	11/29/05
--------------------	--------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.